Spider venom administration impairs glioblastoma growth and modulates immune response in a non-clinical model.
Animals
Antineoplastic Agents
/ therapeutic use
Cell Line, Tumor
Enzyme-Linked Immunosorbent Assay
Female
Flow Cytometry
Fluorescent Antibody Technique
Glioblastoma
/ drug therapy
Humans
Immunity
/ drug effects
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Neoplasm Transplantation
Spider Venoms
/ therapeutic use
Spiders
X-Ray Microtomography
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 04 2020
03 04 2020
Historique:
received:
07
11
2019
accepted:
17
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Molecules from animal venoms are promising candidates for the development of new drugs. Previous in vitro studies have shown that the venom of the spider Phoneutria nigriventer (PnV) is a potential source of antineoplastic components with activity in glioblastoma (GB) cell lines. In the present work, the effects of PnV on tumor development were established in vivo using a xenogeneic model. Human GB (NG97, the most responsive line in the previous study) cells were inoculated (s.c.) on the back of RAG
Identifiants
pubmed: 32246025
doi: 10.1038/s41598-020-62620-9
pii: 10.1038/s41598-020-62620-9
pmc: PMC7125223
doi:
Substances chimiques
Antineoplastic Agents
0
Phalpha1beta toxin, Phoneutria nigriventer
0
Spider Venoms
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5876Références
Thakkar, J. P. et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev. 23(10), 1985–1996 (2014).
doi: 10.1158/1055-9965.EPI-14-0275
Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15, ii1–ii56 (2013).
doi: 10.1093/neuonc/not151
Smoll, N. R., Schaller, K. & Gautschi, O. P. Long-term survival of patients with glioblastoma multiforme (GBM). J. Clin. Neurosci. 20(5), 670–675 (2013).
doi: 10.1016/j.jocn.2012.05.040
Alifieris, C. & Trafalis, D. T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 152, 63–82 (2015).
doi: 10.1016/j.pharmthera.2015.05.005
Patridge, E., Gareiss, P., Kinch, M. S. & Hoyer, D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov. Today. 21(2), 204–207 (2016).
doi: 10.1016/j.drudis.2015.01.009
Escoubas, P. Molecular diversification in spider venoms: a web of combinatorial peptide libraries. Mol. Divers. 10(4), 545–554 (2006).
doi: 10.1007/s11030-006-9050-4
Rapôso, C. Scorpion and spider venoms in cancer treatment: state of the art, challenges, and perspectives. J. Clin. Transl. Res. 3(2), 233–249 (2017).
pubmed: 30873475
pmcid: 30873475
Lima, M. E. et al Phoneutria nigriventer Venom and Toxins: A Review. In: Gopalakrishnakone, P., Corzo, G. A., Lima, M. E. & Garc, E. D., Ed. Spider Venom. Netherlands: Springer, 1–24 (2015).
Cruz-Höfling, M. A., Tavares, J. C. & Rapôso, C. Phoneutria nigriventer venom: action in the central nervous system. In: Gopalakrishnakone, P., Corzo, G. A., Lima, M. E. & Garc, E. D., Ed. Spider Venom. Netherlands: Springer, 175–202 (2015).
Rapôso, C., Zago, G. M., Silva, G. & Cruz-Höfling, M. A. Acute blood brain barrier permeabilization in rats after systemic Phoneutria nigriventer venom. Brain Res. 1149, 18–29 (2007).
doi: 10.1016/j.brainres.2007.02.086
Rapôso, C. et al. Effect of Phoneutria nigriventer venom on the expression of junctional protein and P-gp efflux pump function in the blood-brain barrier. Neurochem. Res. 37(9), 1967–1981 (2012).
doi: 10.1007/s11064-012-0817-y
Rapôso, C. et al. Triggering of protection mechanism against Phoneutria nigriventer spider venom in the brain. Plos One. 9(9), e107292 (2014).
doi: 10.1371/journal.pone.0107292
Rapôso, C. et al. Neuropharmacological effects of Phoneutria nigriventer venom on astrocytes. Neurochem. Int. 96, 13–23 (2016).
doi: 10.1016/j.neuint.2016.04.005
Santos, N. B. et al. Venom of the Phoneutria nigriventer spider alters the cell cycle, viability and migration of cancer cells. J. Cell Physiol. 234(2), 1398–1415 (2018).
doi: 10.1002/jcp.26935
Grippo, M. C., Penteado, P. F., Carelli, E. F., Cruz-Höfling, M. A. & Verinaud, L. Establishment and partial characterization of a continuous human malignant glioma cell line: NG97. Cell Mol. Neurobiol. 21(4), 421–428 (2001).
doi: 10.1023/A:1012662423863
Schenka, A. A. et al. Immunophenotypic and ultrastructural validation of a new human glioblastoma cell line. Cell Mol. Neurobiol. 25(5), 929–941 (2005).
doi: 10.1007/s10571-005-4959-1
Machado, C. M. et al. Morphological characterization of a human glioma cell line. Cancer Cell Int. 5(1), 13 (2005).
doi: 10.1186/1475-2867-5-13
Machado, C. M. et al. Characterization of cells recovered from the xenotransplanted NG97 human-derived glioma cell line subcultured in a long-term in vitro. BMC Cancer. 8, 291 (2008).
doi: 10.1186/1471-2407-8-291
Machado, C. M. et al. Ultrastructural characterization of the new NG97ht human-derived glioma cell line using two different electron microscopy technical procedures. Micrcosc. Res. Tech. 72(4), 310–316 (2009).
doi: 10.1002/jemt.20653
Marim, F. M., Silveira, T. N., Lima, D. S. Jr & Zamboni, D. S. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One. 5(12), e15263 (2010).
doi: 10.1371/journal.pone.0015263
Vogel, D. Y. et al. Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. J. Neuroinflammation. 11, 23 (2014).
doi: 10.1186/1742-2094-11-23
Campbell, J. M. et al. Methotrexate induced toxicity pharmacogenetics: an umbrella review of systematic reviewers and meta-analyses. Cancer Chemother. Pharmacol. 78(1), 27–39 (2016).
doi: 10.1007/s00280-016-3043-5
Cooper, I. et al. Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors. J. Cereb. Blood Flow Metab. 35(6), 967–976 (2015).
doi: 10.1038/jcbfm.2015.6
Shangguan, C. et al. Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT. Theranostics. 8(5), 1376–1388 (2018).
doi: 10.7150/thno.22717
Le Sueur, L. P., Kalapothakis, E. & Cruz-Höfling, M. A. Breakdown of the blood-brain barrier and neuropathological changes induced by Phoneutria nigriventer spider venom. Acta Neuropathol. 105(2), 125–134 (2003).
doi: 10.1007/s00401-002-0623-8
Cruz-Höfling, M. A., Zago, G. M., Melo, L. L. & Rapôso, C. c-FOS and n-NOS reactive neurons in response to circulating Phoneutria nigriventer spider venom. Brain Res. Bull. 73(1-3), 114–126 (2007).
doi: 10.1016/j.brainresbull.2007.01.017
Pathpedia – e-Atlas Histopathology/Brain & cord. Glioblastoma (GBM). ID: BR006.1. PathPedia, LLC © 2006-2019, https://www.pathpedia.com/education/eatlas/histopathology/brain_and_cord/glioblastoma_(gbm).aspx (2019).
Habberstad, A. H., Lind-Landström, T., Sundstrøm, S. & Torp, S. H. Primary human glioblastomas - prognostic value of clinical and histopathological parameters. Clin. Neuropathol. 31(5), 361–368 (2012).
doi: 10.5414/NP300439
Wang, W., Zhou, H. & Liu, L. Side effects of methotrexate therapy for rheumatoid arthitis: A systematic review. Eur. J. Med. Chem. 158, 502–216 (2018).
doi: 10.1016/j.ejmech.2018.09.027
Kaydok, E. & Salbas, E. Thrombocytosis development due to the methotrexate in a patient with rheumatoid arthritis. Rheumatology (Sunnyvale). 8(2), 236 (2018).
doi: 10.4172/2161-1149.1000236
Ravelli, A. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 135(3), 316–320 (1999).
doi: 10.1016/S0022-3476(99)70127-7
Kenis, Y., Michel, J. & Tagnon, H. J. Thrombocytosis, methotrexate, and citrovorum factor. The Lancet. 1(7647), 621 (1970).
doi: 10.1016/S0140-6736(70)91665-X
Campillo, N. et al. Differential oxygenation in tumor microenvironment modulates macrophages and cancer cell crosstalk: novel experimental setting and proof of concept. Front. Oncol. 9, 43 (2019).
doi: 10.3389/fonc.2019.00043
Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J. & Biswas, S. K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17(1), 34–40 (2016).
doi: 10.1038/ni.3324
Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat Rev. Immunol. 8(12), 958–969 (2008).
doi: 10.1038/nri2448
Rodell, C. B. et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578–588 (2018).
doi: 10.1038/s41551-018-0236-8
Xiao, M., Zhang, J., Chen, W. & Chen, W. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J. Exp. Clin. Cancer Res. 37(1), 143–158 (2018).
doi: 10.1186/s13046-018-0815-2
Gordon, S. & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity. 32, 593–604 (2010).
doi: 10.1016/j.immuni.2010.05.007
Kelly, B., Tannahill, G. M., Murphy, M. P. & O’Neill, L. A. Metformin inhibits the production of reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J. Biol. Chem. 290(33), 20348–20359 (2015).
doi: 10.1074/jbc.M115.662114
Nicoletti, N. F. et al. Pre-clinical evaluation of voltage-gated calcium channel blockers derived from the spider P. nigriventer in glioma progression. Toxicon. 129, 58–67 (2017).
doi: 10.1016/j.toxicon.2017.02.001